Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Modus Therapeutics Holding AB's PB Ratio or its related term are showing as below:
OSTO:MODTX'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 7.88
Current: 7.88
During the past 7 years, Modus Therapeutics Holding AB's highest PB Ratio was 7.88. The lowest was 0.00. And the median was 0.00.
OSTO:MODTX's PB Ratio is ranked worse than 80.54% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs OSTO:MODTX: 7.88
During the past 12 months, Modus Therapeutics Holding AB's average Book Value Per Share Growth Rate was 226.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Modus Therapeutics Holding AB was 4.30% per year. The lowest was -60.90% per year. And the median was 1.50% per year.
Back to Basics: PB Ratio
Modus Therapeutics Holding AB (OSTO:MODTX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Modus Therapeutics Holding AB PB Ratio Related Terms
Modus Therapeutics Holding AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MODTX vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Modus Therapeutics Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modus Therapeutics Holding AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Modus Therapeutics Holding AB's PB Ratio falls into.
Modus Therapeutics Holding AB PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Modus Therapeutics Holding AB (OSTO:MODTX) has a PB Ratio of 7.88 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Modus Therapeutics Holding AB and its competitors. According to the industry distribution chart, Modus Therapeutics Holding AB ranks #989 out of 1228 companies in the Biotechnology industry, placing it in the top 80.5%.
Is Modus Therapeutics Holding AB's PB Ratio too high?
Modus Therapeutics Holding AB's current PB Ratio is 7.88. The Biotechnology industry median PB Ratio is 2.89. Modus Therapeutics Holding AB's value of 7.88 is 173.1% above this industry median. Based on the distribution chart, Modus Therapeutics Holding AB ranks #989 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Modus Therapeutics Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Modus Therapeutics Holding AB ranks #989 out of 1228 companies for PB Ratio. This places Modus Therapeutics Holding AB in the lower half of its industry. The industry median PB Ratio is 2.89. Modus Therapeutics Holding AB's value of 7.88 is 173.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modus Therapeutics Holding AB's current PB Ratio of 7.88 is 173.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Modus Therapeutics Holding AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modus Therapeutics Holding AB's current PB Ratio is 7.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current PB Ratio of 7.88. The current PB Ratio is 7.88 and 173.1% above the Biotechnology industry median of 2.89. Modus Therapeutics Holding AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current PB Ratio is 7.88 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modus Therapeutics Holding AB Business Description
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
30GF Score
Get the complete analysis for OSTO:MODTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MODTX has been successfully added to your 
